Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.15 | N/A | +51.61% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.15 | N/A | +51.61% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautious optimism regarding the company's ongoing projects. They emphasized the importance of their pipeline while not providing specific revenue guidance.
Management highlighted progress in their pipeline despite the lack of revenue guidance.
They expressed confidence in future developments but acknowledged challenges ahead.
Alnylam Pharmaceuticals reported a smaller-than-expected loss per share, which led to a slight increase in their stock price. The positive EPS surprise suggests that the company is managing expenses effectively, even though revenue details were not disclosed. Investors may view this as a sign of potential future growth, but the lack of guidance leaves some uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHENIERE ENERGY INC
May 3, 2013